Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo, Omicsoft Integrate Next-Gen Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Omicsoft and GeneGo have partnered to integrate their respective next-generation sequencing software and data-mining platforms, GeneGo said today.

Under the partnership, the companies have integrated Omicsoft's Array Studio and GeneGo's MetaCore data-mining suite.

The Array Studio package provides statistics analysis and visualization tools for 'omics data and supports analysis of next-gen sequencing data, with algorithms designed for the Illumina (Solexa), Roche 454, and Life Technologies sequencing systems.

The platform supports exon junction detection, fusion gene detection, expression value calculation, and mutation reporting and annotation for analysis of sequence runs and lists of modified genes and polymorphisms.

"Pathway and network analysis is a natural next step for these complex [next-gen sequencing] data, and we are glad that we can provide our customers with a seamlessly integrated workflows from raw sequence data to biologically meaningful hypotheses on biomarkers, drug targets, and drug repositioning," GeneGo VP of Business Development Julie Bryant said in a statement.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.